Table 3

Cardiac events in intermediate-/high-risk participants randomized to no screening versus screening

Framingham score: intermediate/high risk (n = 840)PHR (95% CI)
No screening (n = 422)Screening (n = 418)
Primary cardiac events15 (3.6)13 (3.1)0.710.87 (0.41–1.83)
Secondary cardiac events13 (3.1)17 (4.1)0.451.32 (0.64–2.72)
Revascularizations41 (9.7)25 (6.0)0.050.61 (0.37–1.01)
UKPDS risk engine: intermediate/high risk (n = 589)
No screening (n = 298)Screening (n = 291)
Primary cardiac events11 (3.7)14 (4.8)0.511.30 (0.59–2.86)
Secondary cardiac events11 (3.7)12 (4.1)0.791.12 (0.49–2.53)
Revascularizations31 (10.4)25 (8.6)0.480.83 (0.49–1.4)
ALFEDIAM/SFC criteria: high risk (n = 713)
No screening (n = 361)Screening (n = 352)
Primary cardiac events11 (3.1)13 (3.7)0.611.23 (0.55–2.75)
Secondary cardiac events12 (3.3)18 (5.1)0.211.59 (0.77–3.31)
Revascularizations31 (8.6)22 (6.3)0.270.74 (0.43–1.27)
Metabolic syndrome: yes (n = 804)
No screening (n = 406)Screening (n = 398)
Primary cardiac events14 (3.5)10 (2.5)0.420.72 (0.32–1.62)
Secondary cardiac events12 (3.0)15 (3.8)0.551.26 (0.59–2.70)
Revascularizations31 (7.6)23 (5.8)0.310.76 (0.44–1.3)
  • Data are n (%), unless otherwise indicated.